Table 3.
Vitamin D Deficiency and Clinical Factors Associated With Ovulation in PPCOS II
| OR | 95% CI | AOR a | 95% CI | P | |
|---|---|---|---|---|---|
| Vitamin D status | 0.03 | ||||
| 25(OH)D ≥ 20 | 1.00 | — | 1.00 | — | |
| 25(OH)D < 20 | 0.79 | 0.68–0.94 | 0.81 | 0.67–0.98 | |
| Race | <0.0001 | ||||
| White | 1.00 | — | 1.00 | — | |
| Black | 2.0 | 1.52–2.52 | 2.36 | 1.794–3.104 | |
| Other | 1.5 | 1.06–2.14 | 1.326 | 0.916–1.920 | |
| BMI | <0.0001 | ||||
| <30 | 1.00 | — | 1.00 | — | |
| ≥30 | 0.54 | 0.45–0.64 | 0.546 | 0.434–0.687 | |
| Treatment | <0.0001 | ||||
| Letrozole | 1.00 | — | 1.00 | — | |
| Clomiphene | 0.58 | 0.49–0.68 | 0.567 | 0.477–0.675 | |
| AMH | 0.97 | 0.95–0.98 | 0.947 | 0.932–0.961 | <0.0001 |
| LH | 1.02 | 1.01–1.04 | 1.01 | 1.0–1.024 | 0.04 |
| Quartiles of total testosterone, ng/dL | 0.04 | ||||
| Q1 (4–33.1) | 1.00 | — | 1.00 | — | |
| Q2 (33.2–49.3) | 0.90 | 0.71–1.14 | 1.04 | 0.81–1.33 | |
| Q3 (49.5–66.6) | 0.78 | 0.61–1.00 | 1.01 | 0.77–1.31 | |
| Q4 (66.7–226) | 0.53 | 0.42–0.68 | 0.74 | 0.56–0.98 | |
| HOMA IR categories of insulin resistance | 0.0003 | ||||
| Normal | 1.0 | — | 1.00 | — | |
| Moderate | 0.68 | 0.55–0.84 | 0.89 | 0.7–1.13 | |
| Severe | 0.5 | 0.42–0.61 | 0.63 | 0.5–0.79 |
a
AOR for race, obesity, treatment received during PPCOS II (Clomid vs letrozole), AMH, LH, testosterone, and degree of insulin resistance.